Cancer Database Query Results

Liver, Liver Cancer: Click to Expand ⟱
Liver Cancer
Scientific Papers found: Click to Expand⟱
4442- ,    Anticancer and Hepatoprotective Role of Selenium Nanoparticles against
- in-vivo, Liver, HepG2 - NA, Nor, NA
*hepatoP↑, AntiCan↑,
5434- AG,    Recent Advances in the Mechanisms and Applications of Astragalus Polysaccharides in Liver Cancer Treatment: An Overview
- Review, Liver, NA
AntiCan↑, Apoptosis↑, TumCP↓, EMT↓, Imm↑, ChemoSen↑, BioAv↓, TumCG↓, IL2↑, IL12↑, TNF-α↑, P-gp/ABCB1↓, MDR1↓, QoL↑, Casp↑, DNAdam↑, Bcl-2↓, BAX↑, MMP↓, Cyt‑c↑, NOTCH1↓, GSK‐3β↓, TumCCA↑, GSH↓, ROS↑, lipid-P↑, c-Iron↑, GPx4↓, ACSL4↑, Ferroptosis↑, Wnt↓, β-catenin/ZEB1↓, cycD1/CCND1↓, Akt↓, PI3K↓, mTOR↓, CXCR4↓, Vim↓, PD-L1↓, eff↑, eff↑, ChemoSen↑, ChemoSen↑, chemoP↑,
5236- AgNPs,    Adaptive regulations of Nrf2 alleviates silver nanoparticles-induced oxidative stress-related liver cells injury
- in-vitro, Liver, HepG2 - in-vitro, Nor, L02
tumCV↓, ROS↑, *ROS↑, DNAdam↑, *DNAdam↑, eff↓, selectivity↑,
5237- AgNPs,    Nrf2 Activation Mitigates Silver Nanoparticle-Induced Ferroptosis in Hepatocytes
- in-vitro, Liver, HepG2
Ferroptosis↑, p62↑, NRF2↝, eff↓,
4391- AgNPs,    Silver Nanoparticles Induce Apoptosis in HepG2 Cells through Particle-Specific Effects on Mitochondria
- NA, Liver, HepG2
Apoptosis↑,
4390- AgNPs,    Therapeutic Potential of Cucumis melo (L.) Fruit Extract and Its Silver Nanopartciles Against DEN-Induced Hepatocellular Cancer in Rats
- in-vivo, Liver, NA
hepatoP↑, AST↓, ALAT↓, ALP↓,
4387- AgNPs,    Attenuation of diethylnitrosamine (DEN) - Induced hepatic cancer in experimental model of Wistar rats by Carissa carandas embedded silver nanoparticles
- in-vitro, Liver, NA
IL6↓, TNF-α↓, IL1β↓, hepatoP↑,
4385- AgNPs,    Hepatoprotective effect of engineered silver nanoparticles coated bioactive compounds against diethylnitrosamine induced hepatocarcinogenesis in experimental mice
- in-vitro, Liver, NA
hepatoP↑, *AST↓, *ALAT↓, *Catalase↑, *GPx↑, *GSTA1↑, *SOD↑,
4361- AgNPs,  GoldNP,    Biocompatible silver, gold and silver/gold alloy nanoparticles for enhanced cancer therapy: in vitro and in vivo perspectives
- in-vivo, Liver, HepG2
TumCD↑, TumVol↓, *toxicity↝, hepatoP↑,
4429- AgNPs,    Comparative proteomic analysis reveals the different hepatotoxic mechanisms of human hepatocytes exposed to silver nanoparticles
- in-vitro, Liver, HepG2
*toxicity↝, selectivity↑, mt-ROS↑,
4433- AgNPs,    Advancements in metal and metal oxide nanoparticles for targeted cancer therapy and imaging: Mechanisms, applications, and safety concerns
- in-vitro, Liver, HepG2 - in-vitro, Nor, L02
selectivity↑, selectivity↓, mt-ROS↑,
4381- AgNPs,    Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells
- in-vitro, Liver, HepG2
eff↓, ROS↑, other↑,
4373- AgNPs,    In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells
- in-vitro, Liver, HepG2
TumCD↑,
4371- AgNPs,    Effects of Green Silver Nanoparticles on Apoptosis and Oxidative Stress in Normal and Cancerous Human Hepatic Cells in vitro
- in-vitro, Liver, HUH7
ROS↑, selectivity↑, DNAdam↑, Apoptosis↑, GSH↓, lipid-P↑, MMP↓, DNAdam↑,
4370- AgNPs,    Effect of silver nanoparticles in the induction of apoptosis on human hepatocellular carcinoma (HepG2) cell line
- in-vitro, Liver, HepG2
tumCV↓, ROS↑, Apoptosis↑,
4560- AgNPs,    Exploiting antidiabetic activity of silver nanoparticles synthesized using Punica granatum leaves and anticancer potential against human liver cancer cells (HepG2)
- in-vitro, Liver, HepG2 - in-vitro, Diabetic, NA
AntiCan↑, Dose↝, *antiOx↑, *AntiDiabetic↑, *Bacteria↓,
4555- AgNPs,    Silver nanoparticles from Dendropanax morbifera Léveille inhibit cell migration, induce apoptosis, and increase generation of reactive oxygen species in A549 lung cancer cells
- in-vitro, Lung, A549 - in-vitro, Liver, HepG2
*Bacteria↓, tumCV↓, selectivity↑, ROS↑, Apoptosis↑, TumCMig↓, AntiCan↑,
5146- AgNPs,    Silver Nanoparticle-Induced Autophagic-Lysosomal Disruption and NLRP3-Inflammasome Activation in HepG2 Cells Is Size-Dependent
- in-vitro, Liver, HepG2
TumAuto↑, EPR↑, LC3B↑, CHOP/DDIT3↑, ER Stress↑, NLRP3↑, Casp1↓,
341- AgNPs,    Bioprospecting a native silver-resistant Bacillus safensis strain for green synthesis and subsequent antibacterial and anticancer activities of silver nanoparticles
- in-vitro, Liver, HepG2
TumCD↑, ROS↑,
344- AgNPs,    Cytotoxicity and ROS production of manufactured silver nanoparticles of different sizes in hepatoma and leukemia cells
- in-vitro, Liver, HepG2
ROS↑, GSH↓,
369- AgNPs,    Silver nanoparticles induce oxidative cell damage in human liver cells through inhibition of reduced glutathione and induction of mitochondria-involved apoptosis
- in-vitro, Liver, NA
ROS↑, GSH↓, DNAdam↑, lipid-P↝, Apoptosis↑, BAX↑, Bcl-2↓, MMP↓, Casp9↑, Casp3↑, JNK↑,
2835- AgNPs,  Gluc,    Carbohydrate functionalization of silver nanoparticles modulates cytotoxicity and cellular uptake
- in-vitro, Liver, HepG2
Dose↝, eff↑, ROS↑, eff↝, eff↑, eff↝, eff↑, eff↝,
250- AL,    Allicin Induces p53-Mediated Autophagy in Hep G2 Human Liver Cancer Cells
- in-vitro, Liver, HepG2
P53↓, PI3K↓, mTOR↓, Bcl-2↓, AMPK↑, TSC2↑, Beclin-1/ATG6↑, TumAuto↑, tumCV↓, ATG7↑, MMP↓,
233- AL,  5-FU,    Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway
- in-vivo, Liver, NA
ROS↑, MMP↓, Casp3↑, PARP↑, Bcl-2↓,
259- ALA,    Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells
- in-vitro, Liver, HepG2 - in-vitro, Liver, FaO
Cyc↓, P21↑, ROS↑, p‑P53↑, BAX↑, Cyt‑c↑, Casp↑, survivin↓, JNK↑, Akt↓,
5326- ALC,    L-Carnitine Is an Endogenous HDAC Inhibitor Selectively Inhibiting Cancer Cell Growth In Vivo and In Vitro
- vitro+vivo, Liver, HepG2
TumCG↓, P21↑, ac‑H3↑, HDAC↓, *ATP↑, selectivity↑, ac‑H4↑,
1539- Api,  LT,    Dietary flavones counteract phorbol 12-myristate 13-acetate-induced SREBP-2 processing in hepatic cells
- in-vitro, Liver, HepG2
SREBP2↓, eff↑, p‑MEK↓, p‑ERK↓,
1558- Api,    Preparation, characterization and antitumor activity evaluation of apigenin nanoparticles by the liquid antisolvent precipitation technique
- in-vitro, Liver, HepG2
BioAv↑, *toxicity∅, eff↑,
3384- ART/DHA,    Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression
- in-vitro, Liver, Hep3B - in-vitro, Liver, HUH7 - in-vitro, Liver, HepG2
Ferroptosis↑, ROS↑, GSH↓, UPR↑, GPx4↓, PERK↑, eIF2α↑, ATF4↑,
5132- ART/DHA,    Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1
- in-vitro, Liver, HepG2 - in-vitro, BC, MCF7
Iron↓, TfR1/CD71↓, ROS↑,
2320- ART/DHA,    Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis
- in-vitro, AML, K562 - in-vitro, Liver, HepG2
Glycolysis↓, GlucoseCon↓, lactateProd↓, GLUT1↓, PKM2↓, ECAR↓, LDHA↓, cMyc↓, other↝,
2578- ART/DHA,  RES,    Synergic effects of artemisinin and resveratrol in cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Dose↝, TumCMig↓, Apoptosis↑, necrosis↑, ROS↑, eff↑,
1361- Ash,  SRF,    Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells
- in-vitro, Liver, HUH7 - in-vivo, Liver, HUH7
TrxR↓, ROS↑, DNA-PK↑, ER Stress↑, Apoptosis↑, eff↓,
1180- Ash,    Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis
- in-vitro, Liver, HepG2
IDH1↑, Glycolysis↓, P53↑, Hif1a↓,
5369- AV,    Assessment of Anticancer Effects of Aloe vera on 3D Liver Tumor Spheroids in a Microfluidic Platform
- in-vitro, Liver, HepG2
tumCV↓, AntiCan↑, P53↑, Bcl-2↓,
5546- BBM,    Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca²⁺/calmodulin-dependent protein kinase II
- vitro+vivo, Liver, NA
TumCP↓, CaMKII ↓,
2022- BBR,  GoldNP,  Rad,    Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition
- in-vitro, Liver, SMMC-7721 cell - in-vitro, Nor, HL7702
*toxicity↓, radioP↑, BioAv↑, AntiTum↑, selectivity↑, eff↑, chemoP↑,
1405- BBR,  Chit,    Chitosan/alginate nanogel potentiate berberine uptake and enhance oxidative stress mediated apoptotic cell death in HepG2 cells
- in-vitro, Liver, HepG2
*BioAv↑, ROS↑, MMP↓, TumCP↓,
2680- BBR,  PDT,    Photodynamic therapy-triggered nuclear translocation of berberine from mitochondria leads to liver cancer cell death
- in-vitro, Liver, HUH7
TumCD↑, ROS↑, TumCCA↑, ER Stress↑,
2707- BBR,    Berberine exerts its antineoplastic effects by reversing the Warburg effect via downregulation of the Akt/mTOR/GLUT1 signaling pathway
- in-vitro, Liver, HepG2 - in-vitro, BC, MCF7
GLUT1↓, Akt↓, mTOR↓, ATP↓, GlucoseCon↓, TumCP↓, Warburg↓, selectivity↑, TumCCA↑, Glycolysis↓,
2683- BBR,    Berberine reduces endoplasmic reticulum stress and improves insulin signal transduction in Hep G2 cells
- in-vitro, Liver, HepG2
JNK↓, p‑PERK↓, p‑eIF2α↓, *ER Stress↓,
5513- bemA,    ACLY inhibition promotes tumour immunity and suppresses liver cancer
- in-vitro, Liver, NA
ACLY↓, AMPK↑, eff↑, other↝, eff↝,
5592- BetA,    Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Casp3↑, Casp9↑, cl‑PARP↑, Apoptosis↑, Cyt‑c↑, MMP↓,
2762- BetA,    Targeting Effect of Betulinic Acid Liposome Modified by Hyaluronic Acid on Hepatoma Cells In Vitro
- in-vitro, Liver, HepG2
ROCK1↓, RAS↓, *BioAv↓, BioAv↑,
764- Bor,    Effect of Tumor Microenvironment on Selective Uptake of Boric Acid in HepG2 Human Hepatoma Cells
- in-vitro, Liver, HepG2
BioAv↑,
766- Bor,    In vitro effects of boric acid on human liver hepatoma cell line (HepG2) at the half-maximal inhibitory concentration
- in-vitro, Liver, HepG2
TumCCA↑, DNAdam↑, Apoptosis↑,
727- Bor,  RSL3,  erastin,    Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy
- in-vitro, Liver, HepG2
ROS↑, GSH↓, TBARS↑, Ferroptosis↑, ChemoSen↑,
7973- BUL,    Bullatacin, a potent antitumor annonaceous acetogenin, inhibits proliferation of human hepatocarcinoma cell line 2.2.15 by apoptosis induction
- in-vitro, Liver, HepG2
Apoptosis↑, TumCP↓,
7978- BUL,    Synthesis and Cytotoxic Property of Annonaceous Acetogenin Glycoconjugates
- in-vitro, Cerv, HeLa - in-vitro, Lung, A549 - in-vitro, Liver, HepG2
*toxicity↑, *BioAv↑,
5749- CA,  Z,  Rad,    Antitumor and Radiosensitizing Effects of Zinc Oxide-Caffeic Acid Nanoparticles against Solid Ehrlich Carcinoma in Female Mice
- vitro+vivo, BC, MCF7 - NA, Liver, HepG2
RadioS↑, TumVol↓, Bcl-2↓, NF-kB↓, VCAM-1↓, ERK↓, DNAdam↑, TumCCA↑,

Showing Research Papers: 1 to 50 of 169
Page 1 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 169

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

BMP7/OP1↓, 1,   compII↓, 1,   IL13↓, 1,   miR-122-5p↑, 1,   miR-195↑, 1,   miR-199↑, 1,   miR-326-5p↑, 1,   PXR, NR1I2↓, 1,   SUV39H↓, 1,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1,   WEE1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↓, 1,   compI↓, 1,   Fenton↑, 1,   Ferroptosis↑, 5,   GPx4↓, 2,   GPx4↑, 1,   GSH↓, 15,   GSH↑, 2,   GSSG↑, 1,   GSTA1↓, 1,   GSTs↓, 2,   H2O2↑, 3,   HO-1↑, 3,   Iron↓, 1,   Iron↑, 1,   c-Iron↑, 1,   lipid-P↑, 4,   lipid-P↝, 1,   lipidDe↓, 1,   MDA↑, 2,   Mich↑, 1,   NADH↓, 1,   NRF2↑, 4,   NRF2↝, 1,   OXPHOS↓, 1,   PARK2↑, 1,   ROS↓, 3,   ROS↑, 70,   ROS∅, 1,   mt-ROS↑, 3,   SOD↓, 2,   SOD2↑, 1,   TBARS↑, 2,   Trx↓, 1,   Trx↑, 1,   Trx1↓, 1,   Trx2↓, 1,   TrxR↓, 3,   TrxR1↓, 1,   xCT/SLC7A11↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↓, 1,   IronCh↑, 1,   TfR1/CD71↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 6,   ATP↑, 1,   p‑MEK↓, 1,   MMP↓, 29,   mtDam↑, 8,   SDH↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC↓, 1,   ACLY↓, 2,   ACOX1↑, 1,   ACSL4↑, 1,   AKT1↓, 1,   ALAT↓, 3,   AMPK↑, 6,   p‑AMPK↑, 1,   ATG7↑, 1,   cMyc↓, 3,   CPT1A↑, 1,   CYP3A4↓, 1,   DGAT1↓, 1,   ECAR↓, 2,   FASN↓, 2,   G6PD↓, 1,   GAPDH↓, 1,   GLS↓, 1,   glucose↓, 1,   GlucoseCon↓, 5,   GlucoseCon∅, 1,   GlutaM↓, 1,   Glycolysis↓, 6,   HK2↓, 2,   IDH1↑, 1,   IDH2↓, 1,   lactateProd↓, 5,   lactateProd∅, 1,   LAR↓, 1,   LDH↓, 1,   LDH↑, 2,   LDHA↓, 4,   lipoGen↓, 1,   MCT4↓, 1,   OAA↑, 1,   PDK1 / PDPK1↓, 1,   PFK1↓, 1,   PGC1A↑, 1,   PI3k/Akt/mTOR↓, 1,   PKM2↓, 5,   PPP↓, 1,   SCD1↓, 1,   SIRT1↓, 2,   SIRT1↑, 1,   SLC25A1↓, 1,   SREBF2↓, 1,   SREBP1/SREBF1↓, 1,   SREBP2↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

AhR↑, 1,   Akt↓, 11,   p‑Akt↓, 3,   Apoptosis↓, 3,   Apoptosis↑, 57,   ATF2↓, 1,   BAD↑, 1,   BAX↑, 16,   Bax:Bcl2↑, 6,   Bcl-2↓, 17,   Bcl-2↑, 1,   Bcl-2∅, 1,   Bcl-xL↓, 2,   Casp↑, 5,   Casp1↓, 1,   Casp10↑, 1,   Casp12↝, 1,   Casp3↓, 1,   Casp3↑, 24,   cl‑Casp3↑, 6,   Casp7↑, 3,   Casp8↑, 8,   cl‑Casp8↑, 1,   Casp9↑, 9,   cl‑Casp9↑, 2,   Cyt‑c↑, 14,   DR5↑, 3,   FADD↑, 1,   Fas↑, 3,   FasL↑, 1,   Ferroptosis↑, 5,   IAP1↓, 1,   JNK↓, 1,   JNK↑, 4,   p‑JNK↑, 1,   MAPK↑, 2,   Mcl-1↓, 1,   MCT1↓, 2,   necrosis↑, 1,   p27/CDKN1B↑, 1,   p38↑, 2,   p‑p38↑, 1,   Proteasome↓, 1,   PUMA↑, 1,   survivin↓, 4,   TumCD↑, 7,  

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↓, 1,   cSrc↓, 1,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ac‑H3↑, 1,   ac‑H3↝, 1,   ac‑H4↓, 1,   ac‑H4↑, 1,   miR-21↓, 1,   miR-21↑, 1,   other↑, 3,   other↝, 4,   OV6↓, 1,   tumCV↓, 16,   tumCV↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 5,   eIF2α↑, 1,   p‑eIF2α↓, 1,   p‑eIF2α↑, 2,   ER Stress↑, 12,   GRP78/BiP↑, 4,   GRP94↑, 1,   HSP70/HSPA5↓, 2,   HSP70/HSPA5↑, 2,   e-HSP70/HSPA5↓, 1,   HSP90↓, 1,   IRE1↑, 1,   PERK↑, 2,   p‑PERK↓, 1,   p‑PERK↑, 1,   UPR↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↑, 1,   ATG5↑, 2,   Beclin-1/ATG6↑, 4,   Beclin-1/ATG6⇅, 1,   LC3B↑, 1,   LC3II↑, 3,   p62↓, 2,   p62↑, 1,   TumAuto↑, 9,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↓, 1,   DFF45↑, 1,   DNA-PK↑, 1,   DNAdam↑, 14,   P53↓, 2,   P53↑, 16,   p‑P53↑, 1,   PARP↑, 2,   cl‑PARP↑, 11,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK4↓, 2,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 4,   cycD1/CCND1↑, 1,   cycE/CCNE↓, 1,   P21↑, 8,   TumCCA↑, 29,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 1,   CD44↓, 2,   CSCs↓, 1,   EMT↓, 3,   EpCAM↓, 1,   ERK↓, 2,   ERK↑, 3,   p‑ERK↓, 3,   p‑ERK↑, 1,   FOXO4↑, 1,   Gli1↓, 2,   GSK‐3β↓, 2,   HDAC↓, 4,   HH↓, 2,   Let-7↑, 1,   mTOR↓, 6,   mTOR↑, 2,   mTOR⇅, 1,   p‑mTOR↓, 2,   NOTCH1↓, 1,   P70S6K↓, 1,   PI3K↓, 6,   p‑PI3K↓, 1,   PTCH1↓, 1,   PTEN↑, 2,   RAS↓, 2,   Smo↓, 2,   STAT3↓, 6,   p‑STAT3↓, 2,   TOP2↓, 1,   TumCG↓, 18,   Wnt↓, 2,  

Migration(tgid=13) ⓘ

Alix/AIP‑1↓, 2,   AP-1↓, 1,   AP-1↑, 1,   Ca+2↓, 1,   Ca+2↑, 4,   i-Ca+2↑, 2,   CD31/PECAM-1↓, 1,   DLC1↑, 1,   miR-206↑, 1,   miR-22↑, 2,   miR-221↑, 1,   miR-222↑, 1,   proMMP2↓, 1,   MMP9↓, 2,   PKCδ↓, 1,   ROCK1↓, 1,   p‑SMAD2↓, 1,   TGF-β↓, 1,   TSC1↑, 1,   TumCI↓, 3,   TumCMig↓, 5,   TumCP↓, 37,   TumCP∅, 1,   TumMeta↓, 2,   VCAM-1↓, 1,   Vim↓, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 4,   ATF4↑, 2,   EGFR↓, 2,   EPR↑, 2,   HIF-1↓, 1,   Hif1a↓, 9,   miR-126↑, 1,   miR-34b-5p↑, 1,   NO↓, 1,   NO↑, 3,   VEGF↓, 6,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 3,   P-gp/ABCB1↓, 3,   SVCT-2∅, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   COX2/PTGS2↓, 6,   CXCc↓, 1,   CXCR4↓, 1,   DCells↑, 1,   GM-CSF↓, 3,   HCAR1↓, 2,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↑, 1,   p‑IKKα↓, 1,   IL1↓, 1,   IL10↑, 1,   IL12↑, 3,   IL1β↓, 1,   IL2↓, 1,   IL2↑, 1,   IL4↓, 1,   IL4↑, 1,   IL6↓, 5,   IL6↑, 1,   IL8↓, 1,   Imm↑, 1,   JAK↓, 2,   JAK2↓, 1,   Macrophages↑, 1,   MDSCs↓, 1,   MyD88↓, 1,   NF-kB↓, 12,   NF-kB↑, 1,   p‑NF-kB↓, 1,   p65↓, 1,   PD-L1↓, 1,   PGE2↓, 2,   T-Cell↑, 1,   Th1 response?, 1,   TLR1↑, 1,   TLR2↑, 1,   TLR4↓, 2,   TLR4↑, 1,   TNF-α↓, 4,   TNF-α↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 2,   i-pH↑, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 1,   BioAv↑, 5,   ChemoSen↑, 12,   ChemoSen⇅, 1,   Dose?, 2,   Dose↝, 13,   Dose∅, 1,   eff↓, 13,   eff↑, 29,   eff↝, 5,   Half-Life↝, 1,   MDR1↓, 5,   MRP1/ABCC1↓, 1,   P450↓, 1,   RadioS↑, 3,   selectivity↓, 2,   selectivity↑, 29,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 3,   ALP↓, 2,   AST↓, 2,   E6↓, 1,   E7↓, 1,   EGFR↓, 2,   Ferritin↓, 1,   IL6↓, 5,   IL6↑, 1,   LDH↓, 1,   LDH↑, 2,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 10,   AntiTum↑, 3,   chemoP↑, 5,   chemoPv↑, 2,   hepatoP↑, 4,   OS↑, 2,   QoL↑, 1,   radioP↑, 1,   Risk↓, 2,   toxicity↓, 1,   toxicity↑, 1,   toxicity↝, 1,   TumVol↓, 3,   TumVol⇅, 1,   TumW⇅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↑, 1,   CD8+↑, 1,  
Total Targets: 382

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 3,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 9,   Catalase↑, 3,   CYP2E1↓, 1,   GPx↑, 4,   GSH↑, 2,   GSR↑, 1,   GSTA1↑, 1,   H2O2↓, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 2,   ROS↓, 4,   ROS↑, 1,   SOD↑, 4,   VitC↑, 1,   VitE↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,   mtDam↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY∅, 1,   ALAT↓, 1,   p‑AMPK↑, 1,   lipoGen↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↝, 1,   Apoptosis↓, 1,   iNOS↓, 1,   p‑JNK↓, 1,   MAPK↝, 1,   p‑p38↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

STAT3↝, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   Ca+2↓, 1,   i-Ca+2↓, 1,   TGF-β↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 5,   PGE2↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

GR↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 6,   BioEnh↑, 1,   Dose↝, 1,   Half-Life∅, 1,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 2,   AntiTum↑, 1,   cardioP↑, 2,   chemoPv↑, 1,   hepatoP↑, 3,   neuroP↑, 1,   toxicity?, 1,   toxicity↓, 3,   toxicity↑, 2,   toxicity↝, 3,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 4,  
Total Targets: 68

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:14  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page